Targeting a protein to treat Ewing sarcoma in children
Official title: Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma
Funded at Dana-Farber Cancer Inst · NIH-11116836 · Data updated 2026-11-12
This study is looking at a protein called IGF2BP1 to see how it affects the growth of Ewing sarcoma, a type of bone cancer in kids, with the goal of finding better treatments for this tough disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 3, 2024 |
| Project end | April 2, 2027 |
| Funding year | 2025 |
| Award (this year) | $75,520 |
| NIH project number | 5F32CA284750-02 |
| Project ID | NIH-11116836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with Ewing sarcoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of cancers or those who are not diagnosed with Ewing sarcoma may not benefit from this research.
What this research studies
This research focuses on Ewing sarcoma, a serious bone cancer affecting children, and aims to identify a new therapeutic target called IGF2BP1. Using advanced techniques like CRISPR-Cas9, researchers will investigate how knocking out this protein affects cancer cell growth and survival. The study will also explore the underlying mechanisms of how IGF2BP1 contributes to the cancer's biology. By understanding these processes, the research hopes to develop more effective treatments for this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that improve outcomes for children with Ewing sarcoma.
How similar studies have gone: Other research has shown promise in targeting similar proteins in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Bond, Michael Joseph — Dana-Farber Cancer Inst
- Study coordinator: Bond, Michael Joseph
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.